Healthcare Industry News: heart failure
News Release - May 21, 2014
ReliantHeart's HeartAssist5(R) Achieves European CE Mark, Which Includes True Flow Remote MonitoringHOUSTON, TX--(Healthcare Sales & Marketing Network) - The ReliantHeart HeartAssist5® Ventricular Assist Device (VAD) has attained CE Mark approval for design enhancements. The CE Mark which includes remote monitoring via vadlink.com provides remote and true flow measurement of the HeartAssist5®.
The HeartAssist5® (HA5) measures True Flow. Flow is not estimated, it is accurately measured. Now True Flow is available over vadlink.com. This network is further customized for each implanting center so that the real time data is available for monitoring by the implanting center clinicians.
Remote Monitoring via vadlink.com of True Flow, Speed and Power is only available on one VAD: the HA5. HeartAssist5® is the smallest of all Full Flow VADs.
About ReliantHeart, Inc.
ReliantHeart, Inc. is a leading innovator in mechanical circulatory support therapies for advanced stage heart failure. The company manufactures the HeartAssist5®, a next generation ventricular assist device (VAD) which has been granted CE Mark approval for commercial sale in Europe. The HeartAssist5® is an implantable, electric pump designed for use in patients requiring ventricular support due to end stage heart failure and is the world's only fully remotely monitored VAD.
ReliantHeart is privately held and headquartered in Houston, Texas. For more information please visit our website at reliantheart.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.